drugset / Trial / NCT05409547

A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF

NCT05409547

Phase 4 Unknown 80 enrolled Ning Huang
RandomizedParallel-groupDouble-blindTreatment

Summary

Have a comparison between pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) and recombinant human granulocyte-colony stimulating factor (rhG-CSF) for difference in efficacy of hematopoietic reconstruction after autologous peripheral blood stem cell mobilization (PBSCM) and autologous peripheral blood stem cell transplantation (APBSCT). Primary purpose: Compare the difference between PEG-rhG-CSF and G-CSF in PBSCM. Secondary purpose: Compare the difference between PEG-rhG-CSF and G-CSF in APBSCT.

Timeline

Start
2022-06-30
Primary completion
2025-04-30
Completion
2025-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous